Abstract: The invention relates to an administration regimen useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the method further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.

Abstract: The invention relates to a method for data set expansion for improved hypoglycaemia prediction based on classifier ingestion, and comprises the steps of: providing a raw data set for a subject, the data set comprising a plurality of BG values obtained at a given sampling rate and thereto associated time stamps over a plurality of days N, and performing data transformation by rolling scheme temporal binning of evaluation block values (eHH) as input X to create corresponding prediction values (pHH) as output Y, wherein X is created as a sliding window comprising BG values for a given past period of time T?p, and wherein Y is created as an indicator I indicating whether or not a BG value at a given future time T?f is below a given threshold indicative of a hypoglycaemic condition.

Abstract: The invention relates to a novel system to provide data quality control of a subject dataset, useful for treating patients with diabetes mellitus. The data quality control system, via a trained regression model, analyzes blood glucose measurements and provides a predicted insulin injection amount to the subject. The predicted insulin injection amount may be used to improve the accuracy of insulin dose titration programs, providing the subject with confidence that a titrated insulin dose is appropriate and is providing optimal treatment for the diabetes condition. Thus, the data quality control system provides for improved patient outcomes.

Abstract: A device, system and method is provided for predicting risk of hypoglycemia and adjusting an insulin medicament dose size for a subject being on pen based multi-daily injections. A first algorithm is provided for computing a first insulin dose size based on a plurality of timestamped blood glucose (BG) measurements and insulin injected dose sizes. A risk prediction module is adapted to, based on machine learning algorithms, predict risk of hypoglycemia based on the timestamped BG measurements and calculate a second insulin dose size resulting in a non-hypoglycemic state. In case the second dose size is lower than the first dose size, the first dose size is automatically adjusted down to the second dose size and communicated as the recommended dose size to the subject.

Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the device further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.

Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the device further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.